###begin article-title 0
Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression
###end article-title 0
###begin p 1
###xml 172 173 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 1104 1105 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">Patients</span>
###xml 1375 1383 <span type="species:ncbi:9606">patients</span>
This study investigated the possible association of the interleukin-1 beta (IL-1beta) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)n variable number of tandem repeats (VNTR) polymorphism with antidepressant response to paroxetine and mirtazapine treatment. The study group consisted of 101 patients suffering from DSM-IV major depression participating in a randomized double-blind controlled clinical trial. Patients homozygous for the IL-1beta-511T allele had a significantly faster and more pronounced response to paroxetine treatment than IL-1beta-511C allele carriers. No association was found for the IL-1beta C-511T polymorphism with mirtazapine treatment response. The IL-1Ra VNTR showed neither an association with paroxetine nor with mirtazapine treatment response. Our results provide further suggestive evidence that time course of response and antidepressant efficacy of paroxetine, but not of mirtazapine, is influenced in a clinically relevant manner by the IL-1beta C-511T gene variant. Our data do not support the hypothesis that the IL-1Ra (86bp)n VNTR affects antidepressant treatment response to paroxetine or mirtazapine. An independent replication of our finding is needed. If replicated, the IL-1beta C-511T promoter polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 183 200 183 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Hayley et al 2005</xref>
###xml 202 219 202 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Raison et al 2006</xref>
###xml 411 432 408 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Licinio and Wong 1999</xref>
###xml 434 453 431 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Kenis and Maes 2002</xref>
###xml 654 671 648 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Levine et al 1999</xref>
###xml 673 691 667 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Anisman et al 1999</xref>
###xml 693 708 687 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Owen et al 2001</xref>
###xml 710 727 704 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Thomas et al 2005</xref>
###xml 817 836 808 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Kaestner et al 2005</xref>
###xml 860 877 851 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Levine et al 1999</xref>
###xml 919 937 910 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Anisman et al 1999</xref>
###xml 1015 1042 1003 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Brambilla and Maggioni 1998</xref>
###xml 1044 1061 1032 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Kagaya et al 2001</xref>
###xml 1116 1137 1104 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Rothermund et al 2001</xref>
###xml 1475 1492 1463 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Merali et al 1997</xref>
###xml 1494 1517 1482 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Anisman and Merali 1999</xref>
###xml 1519 1534 1507 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Dunn et al 1999</xref>
###xml 1536 1551 1524 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Song et al 1999</xref>
###xml 1705 1725 1690 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Linthorst et al 1995</xref>
###xml 1815 1837 1797 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Ramamoorthy et al 1995</xref>
###xml 1870 1884 1852 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Zhu et al 2006</xref>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 1303 1307 <span type="species:ncbi:10116">rats</span>
###xml 1699 1703 <span type="species:ncbi:10116">rats</span>
A growing body of evidence supports the hypothesis that cytokine activity is involved in the etiology and pathophysiology of behavioral and somatic symptoms of major depression (MD) (Hayley et al 2005; Raison et al 2006). Among the cytokines, animal and clinical studies have demonstrated that interleukin 1beta (IL-1beta) may have a key role in major depression and in the effects of antidepressant treatment (Licinio and Wong 1999; Kenis and Maes 2002). In MD patients, IL-1beta levels have been investigated under several experimental conditions. Some of the results showed an increase in the blood or cerebrospinal fluid (CSF) of depressed patients (Levine et al 1999; Anisman et al 1999; Owen et al 2001; Thomas et al 2005). It was also reported that CSF IL-1beta levels were correlated with depression subtype (Kaestner et al 2005), depression severity (Levine et al 1999), age of onset, and duration of illness (Anisman et al 1999). However, other studies have found that the IL-1beta levels were unchanged (Brambilla and Maggioni 1998; Kagaya et al 2001), and not correlated with the severity of depression (Rothermund et al 2001). To elucidate the complex neurobiological effects of IL-1 in brain, several investigations have been performed in animal models. Systemic administration of IL-1 in rats increased dopamine (DA), norepinephrine (NE), and serotonin (5-HT) activities in hypothalamic nuclei, nucleus accumbens, and limbic regions including the hippocampus (Merali et al 1997; Anisman and Merali 1999; Dunn et al 1999; Song et al 1999). Increases in hippocampal extracellular 5-HT levels have also been found following intracerebroventricular (i.c.v.) administration of IL-1beta in rats (Linthorst et al 1995). IL-1beta has been shown to up-regulate hippocampal expression of the 5-HT transporter (Ramamoorthy et al 1995) and to activate neuronal 5-HT (Zhu et al 2006).
###end p 3
###begin p 4
###xml 146 158 143 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Anisman 2004</xref>
###xml 160 178 157 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Licinio et al 2007</xref>
###xml 320 341 317 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Licinio and Wong 1999</xref>
###xml 388 406 385 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Licinio et al 2007</xref>
###xml 549 571 546 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Maier and Watkins 1995</xref>
###xml 670 687 667 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Kubera et al 2000</xref>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
The action of IL-1beta is regulated by a complex network of molecules including the anti-inflammmtory interleukin-1 receptor antagonist (IL-1Ra) (Anisman 2004; Licinio et al 2007), which represents a naturally occuring endogenous antagonist of IL-1 actions. Several studies support a neuroprotective function of IL-1Ra (Licinio and Wong 1999), which is constitutively expressed in brain (Licinio et al 2007). Additionally, i.c.v. administrated IL-1Ra prevented the development of behavioral deficits in the learned helplessness model of depression (Maier and Watkins 1995). In patients with MD, IL-1Ra serum levels were found to be elevated compared to normal controls (Kubera et al 2000).
###end p 4
###begin p 5
###xml 238 257 238 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Castanon et al 2002</xref>
###xml 259 278 259 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Kenis and Maes 2002</xref>
###xml 410 427 407 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">Suzuki et al 1996</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 410 416 <span type="species:ncbi:8164">Suzuki</span>
Several studies addressed the effects of antidepressive treamtent on cytokine secretion and plasma levels in depressed patients, indicating a normalization of cytokine plasma levels and cytokine production after antidepressant treatment (Castanon et al 2002; Kenis and Maes 2002). However, in brain the chronic administration of antidepressants led to an increased expression of IL-1Ra mRNA and IL-1beta mRNA (Suzuki et al 1996).
###end p 5
###begin p 6
###xml 270 288 264 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Nicklin et al 1994</xref>
###xml 417 438 408 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">di Giovine et al 1992</xref>
###xml 441 469 432 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Pociot and colleagues (1992)</xref>
###xml 904 905 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 948 949 930 931 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1027 1044 1009 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Tarlow et al 1993</xref>
###xml 1157 1180 1139 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Hurme and Santtila 1998</xref>
Taking into account the existing evidence for the close relation between IL-1beta, IL-1Ra and MD, the genes encoding IL-1beta and IL-1Ra can be considered candidate genes for antidepressant treatment response in MD. Both genes map on chromosome 2 in the region q13-q21 (Nicklin et al 1994). A single nucleotide polymorphism (C/T) has been identified in the 5'- regulatory region (position -511) of the IL-1beta gene (di Giovine et al 1992). Pociot and colleagues (1992) demonstrated that individuals homozygous for the IL-1beta-511T allele secreted significantly more IL-1beta than heterozygous individuals, who secreted significantly more than IL-1beta-511C homozygous individuals. Intron 2 of the IL-1Ra gene contains a penta-allelic variable number of tandem repeats (VNTR) of a 86bp sequence (five alleles comprising between two and six repeats). In the general population, the IL-1Ra allele 1 (86bp)4 is more common (0.74) than allele 2 (86bp)2 (0.21); the remaining alleles occur at a combined frequency of less than 5% (Tarlow et al 1993). Functionally, allele 2 was associated with an increased plasma level of IL-1Ra in Finnish healthy volunteers (Hurme and Santtila 1998).
###end p 6
###begin p 7
###xml 183 207 183 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Yu and colleagues (2003)</xref>
###xml 522 523 518 519 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 706 708 702 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2A</sub>
###xml 714 716 710 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2C</sub>
###xml 725 726 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 806 808 802 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 820 845 816 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Anttila and Leinonen 2001</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
Paroxetine is widely and successfully used in the treatment of MD. Like all SSRI, it exerts its antidepressant effects mainly through inhibition of the serotonin transporter (5-HTT). Yu and colleagues (2003) reported that depressed patients homozygous for the -511T allele had a more favorable fluoxetine treatment response than -511C allele carriers, so that one could hypothesize a similar effect in our sample of paroxetine-treated patients. Mirtazapine is an antidepressant that is believed to antagonize central alpha2-receptors located on both noradrenergic and serotonergic neurons. As a result, mirtazapine enhances both the neurotransmission of 5-HT and NE. Additionally, mirtazapine inhibits 5-HT2A, 5-HT2C and 5-HT3 receptors, thereby focusing the enhanced serotonergic neurotransmission on 5-HT1A receptors (Anttila and Leinonen 2001). To our knowledge, there is no previous report on an investigation of IL-1 gene complex variants and mirtazapine treatment response.
###end p 7
###begin p 8
###xml 133 151 133 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Szegedi et al 2005</xref>
###xml 153 170 153 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">Tadi&#263; et al 2007a</xref>
###xml 172 177 172 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">2007b</xref>
###xml 259 260 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
The aim of the present study, which is a part of a more comprehensive clinical genetics project on treatment response in depression (Szegedi et al 2005; Tadic et al 2007a, 2007b), was to investigate the possible effect of the IL-1beta C-511T and IL-1Ra (86bp)n intron 2 polymorphism on the outcome of antidepressant response to paroxetine and mirtazapine treatment in patients with MD.
###end p 8
###begin title 9
Methodology
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 170 178 <span type="species:ncbi:9606">patients</span>
A total of 269 outpatients were enrolled in a multicenter, randomized, double-blind comparison of paroxetine and mirtazapine conducted at 50 centers in Germany. Of these patients, 116 gave written informed consent for the collection of blood samples for DNA genotyping and the analyses of possible associations between genotypes and clinical data (eg, response to treatment). All study components have been approved by the local ethics committees.
###end p 11
###begin p 12
###xml 142 160 142 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Benkert et al 2000</xref>
A more detailed description of the recruitment procedure, treatment schedule, and clinical assessments has been reported in a previous paper (Benkert et al 2000). Briefly, females and males, aged from 18 to 70 years suffering from acute major depressive episode (MDE) with a sum score >/=18 points on the 17-item version of the Hamilton Rating Scale for Depression (HAMD-17) at the start and end of a placebo washout period were eligible for the study. Diagnosis of MDE according to DSM-IV criteria was assigned by eleven clinically experienced research assistants, who underwent several rater trainings prior to the start of the study. Exclusion criteria were the lack of response to at least two adequate antidepressant treatments during the current depressive episode, current episode's duration more than twelve months, more than three previous episodes that did not respond to adequate treatment, a reduction of >/=25% in the HAMD-17 sum score during placebo washout period, suicide risk defined as a score offour to six on item ten of the Montgomery-Asberg-Depression-Rating-Scale (MADRS), history of bipolar affective disorder, depressive disorder not otherwise specified, panic disorder (with or without agoraphobia), agoraphobia without a history of panic disorder, schizophrenia, organic mental disorder, eating disorder, specific phobia, social phobia, or generalized anxiety disorder.
###end p 12
###begin p 13
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
After a 3- to 7-day washout period, patients were randomly assigned to either mirtazapine or paroxetine treatment for six weeks. Mirtazapine was first administered at 15 mg (days 1 and 2), from day 3 onward at 30 mg/day; after 2 weeks, an increased dose of 45 mg/day was given to nonresponders, defined by Clinical Global Impressions scale (CGI) ratings in the therapeutic effect item of "slight" or "unchanged/worsened" and no "outweighs therapeutic efficacy" ratings in the tolerability item. Paroxetine dose was 20 mg/day and could be increased to 40 mg/day after 2 weeks in nonresponders according to the same pre-specified CGI criterion. No concomitant psychotropic treatment was allowed during the study. All patients were assessed at baseline (day 0), and on days 7, 14, 21, 28, and 42 of active treatment using the HAMD-17.
###end p 13
###begin title 14
DNA analysis
###end title 14
###begin p 15
###xml 335 358 332 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Hurme and Santtila 1998</xref>
###xml 1316 1333 1256 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Tarlow et al 1993</xref>
Genotyping was performed blind to treatment and clinical course of the illness. Genomic DNA was prepared from 10 ml blood using the Quiagen Maxi DNA Extraction Kit (Quiagen, Hilden, Germany). Genotyping of the C-511T variant of the IL-1beta gene (dbSNP: rs3087258) was performed using a polymerase chain reaction (PCR) - based method (Hurme and Santtila 1998). A 304-bp PCR fragment of the IL-1beta promoter region was amplified using the primer pair 5'-TGGCATTGATCTGGTTCATC-3' and 5'-GTTTAGGAATCTTCCCACTT-3'. Reaction was performed using 50 ng genomic DNA, 20 pmol of each primer (Invitrogen), 1 U Taq polymerase (Fermentas), 0.1 mM dNTP (Fermentas), 15 mM MgCl2, 60 mM Tris-HCl und 15 mM ammoniumsulfate. PCR conditions were as follows: 95 degreesC for 2 min, 55 degreesC for 1 min, 74 degreesC for 1 min, then 38 cycles of 95 degreesC for 1 min, 55 degreesC for 1 min, 74 degreesC for 1 min and finally 74 degreesC for 4 min. The products were digested with 6 U of AvaI at 37 degreesC for 3h. Fragments were analyzed by electrophoresis and stained with ethidium bromide. This gave products that either remained intact (IL-1beta -511T allele; allele 2) or were cut into two fragments of 190 and 114 bp (IL1beta -511C allele; allele 1). For the analysis of the pentaallelic VNTR within intron 2 of the IL-1Ra gene (Tarlow et al 1993), oligonucleotides 5'-TGGCATTGATCTGGTTCATC-3' and 5'-TCCTGGTCTGCAGGTAA-3' were used as primers in PCR. Reaction was performed using 50 ng genomic DNA, 20 pmol of each primer (Invitrogen), 1 U Taq polymerase (Fermentas), 0.1 mM dNTP (Fermentas), 3.5 mM MgCl2, 60 mM Tris-HCl und 15 mM ammoniumsulfate. PCR conditions were: initial denaturation at 96 degreesC for 1 min followed by 35 cycles at 94 degreesC for 1 min, 60 degreesC for 1 min, 70 degreesC for 1 min and finally 72 degreesC for 5 min. The PCR products were separated by electrophoresis on 2% agarose gel and visualized by ethidium bromide staining. Allele 1 (four repeats) was 410 bp long, allele 2 (two repeats) 240 bp, allele 3 (three repeats) 325 bp, and allele 4 (five repeats) 500 bp.
###end p 15
###begin title 16
Data analysis
###end title 16
###begin p 17
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 211 227 211 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Continuous data:</italic>
###xml 540 563 540 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Mallinckrodt et al 2001</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">2003</xref>
###xml 1447 1448 1435 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1471 1488 1459 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Categorical data:</italic>
###xml 859 867 <span type="species:ncbi:9606">patients</span>
###xml 1011 1019 <span type="species:ncbi:9606">patients</span>
###xml 1069 1077 <span type="species:ncbi:9606">patients</span>
Data analyses were carried out using SPSS (version 12.0). In both treatment groups, clinical and demographic characteristics were compared between genotype groups with one-way ANOVA or t-test, when appropriate. Continuous data: Within treatment groups, HAMD-17 sum score differences between genotype groups across the treatment period were analyzed using a mixed-effects model repeated-measures methodology (MMRM), as MMRM has been shown to provide highly accurate modeling of treatment outcome while accounting for nonrandom missing data (Mallinckrodt et al 2001, 2003). In this model, we included HAMD-17 sum scores as dependent variables. The independent variables time and genotype as well as the interaction time x genotype were included as fixed effects, cases as random effects. Age and gender were included as potential covariates. For this analysis, patients with valid HAMD-17 scores for at least two weeks of treament (and baseline) were included (IL-1beta*paroxetine/IL-1beta*mirtazapine: n = 44/48 patients; IL-1Ra*paroxetine/IL-1Ra*mirtazapine: n = 39/46 patients). Proportions of missing data (IL-1beta*paroxetine/IL-1beta*mirtazapine: 3.4%/3.1%; IL-1Ra*paroxetine/IL-1Ra*mirtazapine: 3.0%/2.5%) were similar in all analyzed groups. Additionally, within the intention-to-treat (ITT) sample HAMD-17 sum score differences between genotype groups were analyzed for each assessment day and the individual endpoint with one-way ANOVA or t-test, if appropriate. Categorical data: Within the ITT sample, differences of time to remission (HAMD-17 sum score </=7) between genotype groups were calculated applying Kaplan-Meier curve analyses (KM) with logrank tests in each treatment group separately. "Survival time" was defined as the time to first occurrence of remission or - in case of nonremission - as the time of the last observation. Again, age and gender were included as potential covariates by means of Cox regression analysis. Additionally, we determined remitters and nonremitters for each assessment day and the individual endpoint. The division by genotype led to clear 2 x 2 contingency tables which were analyzed by Chi-square test. The level of significance was set at 0.05 (two-tailed). A correction for multiple testing was not performed because of the exploratory nature of the study.
###end p 17
###begin title 18
Results
###end title 18
###begin p 19
###xml 311 312 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
One-hundred-and-sixteen patients gave written informed consent. Of the 116 patients, n = 12 patients had to be excluded because of missing HAMD-17 data at baseline. Considering the data for IL-1beta C-511T analysis, n = 3 patients had to be excluded because offailed genotyping. In the case of the IL-1Ra (86bp)n polymorphism, n = 4 patients had to be excluded because offailed genotyping. Almost all patients were IL-1Ra*1 or IL-1Ra*2 allele carriers. In order to minimize the chances of spurious associations with very rare alleles, subjects bearing any of the other alleles (n = 6) were excluded from the analysis. Therefore, the total numbers of patients in the ITT samples differ between the analysis of the IL-1beta (n = 101; females/males: n = 74/27) and the IL-1Ra polymorphism (n = 94; females/males: n = 73/21). With the exception of a lower proportion offemales in the group of patients without genotyping (sex ratio f/m = 1.4 vs. 2.9, p < 0.01), patients with or without genotyping were structurally similar with regard to age, depression severity at baseline and response to double-blind treatment in the trial (age, HAMD-17 sum score at baseline, day 42 and at endpoint, remitter rates at d42 and at endpoint: p > 0.1 for each analysis).
###end p 19
###begin title 20
Genotype distribution, clinical and demographic data
###end title 20
###begin p 21
###xml 63 64 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 158 165 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
The genotype distributions of IL-1beta C-511T and IL-1Ra (86bp)n polymorphisms in our sample as well as clinical and demographic characteristics are shown in Table 1.
###end p 21
###begin p 22
Clinical and demographic characteristics of our sample
###end p 22
###begin p 23
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: Data are presented as mean (SD) unless otherwise indicated.
###end p 23
###begin p 24
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: HAMD-17, Hamilton Rating Scale for Depression (17 items); IL, interleukin.
###end p 24
###begin p 25
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Genotype frequencies of the two analyzed polymorphisms showed no deviation from Hardy-Weinberg equilibrium in both treatment groups. Genotype frequencies of both SNPs did not differ between treatment groups. In paroxetine-treated patients there were no significant differences among the three genotype groups of both polymorphisms in mean age, baseline mean HAMD-17 score or mean daily drug dose (p > 0.05 for each analysis). In mirtazapine-treated patients there were no significant differences of the same clinical and demographical data (p > 0.05 for each analysis), with the exception of younger IL-1beta-511TT-carriers compared with -511CC- and -511CT- bearing patients (F(2) = 3.3; p = 0.045).
###end p 25
###begin title 26
IL-1beta C-511T polymorphism
###end title 26
###begin p 27
###xml 403 411 394 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Paroxetine-treated patients homozygous for the IL-1beta-511T allele displayed a more pronounced response during the course of treatment than IL-1beta-511CT- or -511CC-carriers (data not shown). Therefore, IL-1beta-511CT- and -511CC-carriers were pooled together for further analysis (-511CT/CC). The mean values of the HAMD-17 sum scores divided by genotype groups (-511TT and -511CT/CC) are plotted in Figure 1.
###end p 27
###begin p 28
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Time course of changes in mean HAMD-17 sum score during treatment in paroxetine-treated patients stratified by IL-1beta C-511T genotype groups. * = p < 0.05.
###end p 28
###begin p 29
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 684 685 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1004 1005 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1477 1478 1463 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1527 1528 1513 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 1354 1362 <span type="species:ncbi:9606">patients</span>
The global comparison of HAMD-17 score changes across the course of treatment showed no clear genotype effect (MMRM: F (1,54.6) = 3.4, p = 0.072), but a significant interaction of time x genotype (MMRM: F (5,136.8) = 2.9, p = 0.017). Neither age (main effect: F (1,59.1) = 0.2, p = 0.68) nor gender (main effect: F (1,54.1) = 0.3, p = 0.62; all interactions p > 0.05) had a significant impact on these results and were hence omitted as factors in the final model. Mean HAMD-17 scores at particular time points were lower in -511TT- compared with -511CT/CC-bearing patients from day 14 onwards with statistically significant differences on day 21 (t (41) = 2.3, p = 0.028) and day 28 (t (39) = 2.3, p = 0.025) as well as nonsignificant differences on day 42 (6.2 +/- 4.7 vs. 10.4 +/- 6.4) and at the endpoint (5.5 +/- 4.5 vs. 11.7 +/- 7.2). Mean time to remission (+/- SE) was significantly shorter in the -511TT-group (29 +/- 6 days) compared with the -511CT/CC-group (36 +/- 2 days) (KM: logrank-test ; p = 0.043). In Cox regression analysis, age (main effect: p = 0.98) and gender (main effect: p = 0.81; all interactions p > 0.1) did not show a statistically significant effect on these results and were thus not included as potential confounders in the final model. Remitter rates were continuously higher in -511TT- compared with -511CT/CC- bearing patients from day 14 onwards (day 14: 33.3 vs. 13.2%) with significant differences on day 21 (50.0 vs. 10.8%; Pearsons's , p = 0.016) and at the endpoint (83.3 vs. 32.5%; ; p = 0.017) as well as nonsignificant differences on day 28 (50.0 vs. 20.0%) and day 42 (80.0 vs. 35.3%).
###end p 29
###begin p 30
###xml 151 159 148 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
The course of mean HAMD-17 scores across the study period in mirtazapine-treated patients stratified by IL-1beta C-511T genotype groups is depicted in Figure 2.
###end p 30
###begin p 31
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Time course of changes in mean HAMD-17 sum score during treatment in mirtazapine-treated patients stratified by IL-1beta C-511T genotype groups.
###end p 31
###begin p 32
###xml 393 401 <span type="species:ncbi:9606">patients</span>
Between genotype groups, there were neither significant differences of HAMD-17 score changes over the treatment period (covariate age: F (1,54.2) = 0.3, p = 0.59; covariate gender: F (1,55.5) = 0.9, p = 0.36; all interactions p > 0.1) nor on particular assessment points (p > 0.05 for each analysis). Mean times to remission (+/- SE) were similar in both -511TT- (33 +/- 6 days) and -511CT/CC-patients (32 +/- 2 days; p > 0.05) without significant effects of age (p = 0.65) and gender (p = 0.67; all interactions p > 0.1) in Cox regression analysis. Proportions of remitters of both genotype groups did not differ significantly at any assessment day of the study (p > 0.05 for each analysis).
###end p 32
###begin title 33
###xml 13 14 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
IL-1Ra (86bp)n polymorphism
###end title 33
###begin p 34
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
A possible impact of the IL-1Ra (86bp)n polymorphism on different treatment response characteristics to paroxetine and mirtazapine was analyzed analogously to the analysis of the IL-1beta C-511T SNP. There were neither clinically meaningful nor statistically significant differences between the three genotype groups IL-1Ra*11, IL-1Ra*12 and IL-1Ra*22 in any analyzed outcome measure (p > 0.05 for each analysis) in paroxetine as well as in mirtazapine-treated patients.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 445 469 436 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Yu and colleagues (2003)</xref>
###xml 968 986 950 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">El-Omar et al 2000</xref>
###xml 1204 1219 1183 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Yu et al (2003)</xref>
###xml 1490 1508 1463 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">Yirmiya et al 2001</xref>
###xml 1510 1529 1483 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Castanon et al 2004</xref>
###xml 1531 1552 1504 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Obuchowicz et al 2006</xref>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 1319 1327 <span type="species:ncbi:9606">patients</span>
Our results provide further suggestive evidence that the IL-1beta C-511T gene variant affects the response to SSRI treatment in patients suffering from major depression. This conclusion is derived from the finding that paroxetine-treated patients with the IL-1beta-511TT genotype showed a faster and more pronounced response to paroxetine than patients carrying the IL-1beta-511CT or -511CC genotype. Our finding is in line with the report from Yu and colleagues (2003), who also reported an advantageous outcome in IL-1beta-511TT-patients to fluoxetine treatment for 4 weeks. The mechanisms responsible for the observed differences in SSRI antidepressant response are not yet established. On the molecular genetic level the effects of the IL-1beta-511 SNP may be mediated by strong linkage disequilibrium with a TATA box polymorphism at position -31 from the starting sequence of the IL-1beta gene affecting protein (presumably transcription factors) binding to DNA (El-Omar et al 2000). Neurobiologically, one could have expected that subjects carrying the more active IL-1beta -511TT genotype are more resistant to antidepressant treatment. However, this was neither the case in the sample studied by Yu et al (2003) nor in our sample. An explanation might be related to higher levels of IL-1beta in -511TT carrying patients compared to IL-1beta-511C carriers. If some of the effect of SSRIs is to diminish the production of central or peripheral proinflammatory cytokines such as IL-1 (Yirmiya et al 2001; Castanon et al 2004; Obuchowicz et al 2006) the response to SSRIs could indeed be greater in IL-1beta-511TT carriers.
###end p 36
###begin p 37
###xml 369 385 355 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">Kraus et al 2002</xref>
###xml 387 396 373 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Kast 2003</xref>
###xml 534 554 517 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Schiepers et al 2005</xref>
In contrast, we found no associaton between the IL-1beta C-511T gene variant and mirtazapine treatment response. This might be related to different immuno-modulatory effects of mirtazapine treatment on IL-1beta. Given that, in contrast to SSRI, mirtazapine treatment was associated with the upregulation of the pro-inflammatory tumor necrosis factor-alpha (TNF-alpha) (Kraus et al 2002; Kast 2003), different effects on IL-1beta seem possible. However, the multiplicity of possible mechanisms of immune modulation by antidepressants (Schiepers et al 2005) suggests that several other reasons might be involved.
###end p 37
###begin p 38
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 355 383 355 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Kubera and colleagues (2000)</xref>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
Additionally, we did not find an association of the IL-1Ra (86bp)n intron 2 polymorphism with antidepressant response to paroxetine and mirtazapine. This result does not support the hypothesis that the IL-1Ra intron 2 VNTR is involved in a mechanism affecting treatment outcome to paroxetine and mirtazapine. This finding is in line with the results from Kubera and colleagues (2000), who reported that IL-1Ra was elevated in depressed patients and did not normalize after response following antidepressant treatment. Thus, based on the available data, it can not be suggested that IL-1Ra is involved in neurobiological mechanisms underlying antidepressant treatment response. However, if the IL-1Ra gene is an uncommon locus affecting antidepressant treatment response or one with relatively modest effects, our power to detect its effects could have been too small.
###end p 38
###begin p 39
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 332 339 <span type="species:ncbi:9606">patient</span>
The herein reported results are preliminary due to some limitations. There were some differences in gender distribution between the groups of non-genotyped and genotyped patients. However, a selective sample selection is improbable because our sample of genotyped patients with more females than males is comparable with many other patient samples in similar investigations and we did not found gender effects on treatment outcome. The small sample size did not allow us to control for unknown population stratification (eg, center effects) and possible influences of comorbid personality disorders. The exclusion criteria may further limit the generalizability of our findings. We did no correction for multiple testing for the obtained p-values. A Bonferroni correction for multiple testing (15 tests in each group) would lead to a corrected threshold of about 0.003 at the 5% significance level. If we perform Bonferroni correction for multiple testing in this exploratory study, all differences are nonsignificant, and thus the results must be interpreted with caution. The sample size is small for a genetic study examining the relationship between six genotypes per group, two polymorphisms and the treatment response. Feasible sample sizes in clinical studies are often too small to identify genetic variations that would withstand correction for multiple testing, unless they conferred major effects. However, this is very unlikely to be the case in phenotypes of complex inheritance where several interacting genes of small effect are predicted to contribute to antidepressant response. To circumvent this dilemma, replications ideally in larger samples will be needed to confirm the association.
###end p 39
###begin p 40
###xml 268 281 262 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Yu et al 2003</xref>
###xml 536 537 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
In conclusion, our results provide further suggestive evidence that the IL-1beta-511TT genotype is associated with an advantageous SSRI treatment response compared with the IL-1beta-511CT/CC genotype, which is in line with previous yet hitherto unreplicated findings (Yu et al 2003). Differences in the mechanisms of action of paroxetine and mirtazapine may account for the divergent effects of the IL-1beta C-511T gene variant on treatment outcome with these substances. Our results do not support the hypothesis that the IL-1Ra (86bp)n intron 2 VNTR is involved in treatment response to paroxetine or mirtazapine in major depression. Replications in large scale studies, which address the limitations of our study, are needed to further clarify the role of the IL-1beta C-511T variant on SSRI treatment response. If replicated, the IL-1beta C-511T promoter polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression.
###end p 40
###begin title 41
References
###end title 41
###begin article-title 42
Considering cytokine panels
###end article-title 42
###begin article-title 43
Anhedonic and anxiogenic effects of cytokine exposure
###end article-title 43
###begin article-title 44
Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features
###end article-title 44
###begin article-title 45
A review of the pharmacological and clinical profile of mirtazapine
###end article-title 45
###begin article-title 46
Mirtazapine compared with paroxetine in major depression
###end article-title 46
###begin article-title 47
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Blood levels of cytokines in elderly patients with major depressive disorder
###end article-title 47
###begin article-title 48
###xml 131 135 <span type="species:ncbi:10116">rats</span>
Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats
###end article-title 48
###begin article-title 49
Effects of antidepressants on cytokine production and actions
###end article-title 49
###begin article-title 50
###xml 40 45 <span type="species:ncbi:9606">human</span>
Single base polymorphism at -511 in the human interleukin-1 beta gene (IL-1 beta)
###end article-title 50
###begin article-title 51
Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress
###end article-title 51
###begin article-title 52
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
###end article-title 52
###begin article-title 53
The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity
###end article-title 53
###begin article-title 54
IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes
###end article-title 54
###begin article-title 55
Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity
###end article-title 55
###begin article-title 56
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan
###end article-title 56
###begin article-title 57
Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels
###end article-title 57
###begin article-title 58
Effects of antidepressants on the production of cytokines
###end article-title 58
###begin article-title 59
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine
###end article-title 59
###begin article-title 60
Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission
###end article-title 60
###begin article-title 61
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Cerebrospinal cytokine levels in patients with acute depression
###end article-title 61
###begin article-title 62
###xml 48 53 <span type="species:ncbi:9606">human</span>
Pharmacogenetics of neuroimmune interactions in human psychiatric disorders
###end article-title 62
###begin article-title 63
The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection
###end article-title 63
###begin article-title 64
Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study
###end article-title 64
###begin article-title 65
Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement offear conditioning and interference with escape produced by inescapable shock
###end article-title 65
###begin article-title 66
Accounting for dropout bias using mixed-effects models
###end article-title 66
###begin article-title 67
Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations
###end article-title 67
###begin article-title 68
Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study
###end article-title 68
###begin article-title 69
###xml 46 51 <span type="species:ncbi:9606">human</span>
A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes
###end article-title 69
###begin article-title 70
###xml 65 68 <span type="species:ncbi:10116">rat</span>
Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures
###end article-title 70
###begin article-title 71
Raised levels of plasma interleukin-1beta in major and postviral depression
###end article-title 71
###begin article-title 72
###xml 27 32 <span type="species:ncbi:9606">human</span>
A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro
###end article-title 72
###begin article-title 73
Cytokines sing the blues: inflammation and the pathogenesis of depression
###end article-title 73
###begin article-title 74
###xml 18 23 <span type="species:ncbi:9606">human</span>
Regulation of the human serotonin transporter by interleukin-1 beta
###end article-title 74
###begin article-title 75
Inflammatory markers in major depression and melancholia
###end article-title 75
###begin article-title 76
Cytokines and major depression
###end article-title 76
###begin article-title 77
Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment
###end article-title 77
###begin article-title 78
###xml 145 148 <span type="species:ncbi:10116">rat</span>
Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain
###end article-title 78
###begin article-title 79
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression
###end article-title 79
###begin article-title 80
A monoamine oxidase B gene variant and short-term antidepressant treatment response
###end article-title 80
###begin article-title 81
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression
###end article-title 81
###begin article-title 82
###xml 16 21 <span type="species:ncbi:9606">human</span>
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat
###end article-title 82
###begin article-title 83
Increase in interleukin-1beta in late-life depression
###end article-title 83
###begin article-title 84
Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents
###end article-title 84
###begin article-title 85
Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response
###end article-title 85
###begin article-title 86
The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters
###end article-title 86

